Metabolomics and risk of Parkinson's Disease

代谢组学和帕金森病的风险

• 批准号: 9313961
• 负责人: ALBERTO ASCHERIO
• 金额: $ 56.31万
• 依托单位: HARVARD SCHOOL OF PUBLIC HEALTH
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-09-01 至 2020-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9313961
• 关键词: Affect; Age; Alanine; American; Archives; Biological Markers; Blood; Blood specimen; Branched-Chain Amino Acids; Caffeine; Cancer Prevention Study II; Choline; Chronic; Chronic Disease; Clinical; Coffee; Cohort Studies; Confounding Factors (Epidemiology); Consumption; Controlled Study; Creatine; Cross-Sectional Studies; Data; Data Collection; Diabetes Mellitus; Diagnosis; Diagnostic; Diet; Disease; Disease Progression; Early Diagnosis; Early identification; Etiology; Event; Failure; Follow-Up Studies; Functional disorder; Funding; Glutamates; Goals; Health Professional; Incidence; Individual; Institutes; Insulin Resistance; Investigation; Life Style; Machine Learning; Measures; Mediating; Medical; Medical History; Metabolic; Metabolic Pathway; Methods; Motor; National Institute of Neurological Disorders and Stroke; Nature; Nerve Degeneration; Neurodegenerative Disorders; Nurses' Health Study; Parkinson Disease; Participant; Patients; Persons; Phase; Physical activity; Plasma; Population; Progressive Disease; Research; Resources; Risk; Risk Factors; Sampling; Smoking; Specificity; Techniques; Therapeutic; Time; United States; United States National Institutes of Health; Update; Urate; Validation; Women' s Health Nursing; Work; acylcarnitine; aging population; base; brain cell; cancer prevention; case control; cigarette smoking; clinical Diagnosis; cohort; design; diabetes risk; disability; disorder risk; follow-up; gender difference; insight; interest; men; metabolic profile; metabolome; metabolomics; mitochondrial dysfunction; motor symptom; neuron loss; novel; novel strategies; nutrition; peripheral blood; pre-clinical; prospective; public health relevance; sex; specific biomarkers; tool

 DESCRIPTION (provided by applicant): Parkinson disease (PD) is the second most common neurodegenerative disease in the United States and affects over one million Americans; this number is growing due to population aging. Current treatments do not prevent the disease progression that ultimately results in severe disability. There is thus a compelling need to develop neuroprotective treatments. Because at the time of the clinical diagnosis of PD there is already substantial neuronal loss, such treatments should ideally be initiated earlier. Aims of the proposed investigation are to implement and validate a novel metabolomic approach for the identification of early changes in peripheral blood of individuals with preclinical or premotor PD. The metabolomic results will be integrated with detailed and validated information on risk factors for PD, which has been collected prospectively and periodically updated. We expect by this means to identify new clues to the etiology of PD and to identify a metabolomic signature of PD that could contribute to an early diagnosis. To achieve these goals, we will take advantage of data and blood samples collected from over 80,000 participants in three large ongoing cohorts, the Nurses' Health Study (NHS), the Health Professional Follow-up Study (HPFS), and the Cancer Prevention Study-II Nutrition, who have been followed for over 25 years for incident Parkinson disease. We expect to include a total of 805 incident cases of PD that will be matched to 805 controls, using a nested case-control design.

 描述(申请人提供)：帕金森病(PD)是美国第二常见的神经退行性疾病，影响着100多万美国人；由于人口老龄化，这个数字还在增长。目前的治疗方法无法阻止最终导致严重残疾的疾病进展。因此，迫切需要开发神经保护疗法。因为在临床诊断帕金森病的时候，已经有大量的神经元丢失，理想的情况下，这种治疗应该更早开始。的目标 建议的研究是实施和验证一种新的代谢学方法来识别临床前或运动前帕金森病患者外周血的早期变化。 代谢学结果将与帕金森病风险因素的详细和验证信息整合在一起，这些信息已被前瞻性地收集并定期更新。我们期望通过这种方法识别帕金森病病因的新线索，并识别有助于早期诊断的帕金森病的代谢特征。为了实现这些目标，我们将利用从护士健康研究(NHS)、健康专业人员后续研究(HPFS)和癌症预防研究-II营养三个大型持续队列中收集的超过80,000名参与者的数据和血液样本，这些参与者已经跟踪帕金森病事件超过25年。我们预计将纳入总共805例帕金森病事件病例，这些病例将与805例对照相匹配，采用嵌套病例对照设计。